RxDoctor Payments Data

Oliver Wisco, DO

MOHS-Micrographic Surgery · Bend, ORNPI 1164545166

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $8,916 of the $12,712 with a category attached, or 70.1%. 25 manufacturers reported payments, led by Sanofi at 46.4% of the total.

$12,712in general payments, 2019–2025

Across 130 payments — averaging $97.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$6K
  • Regeneron Healthcare Solutions, Inc.$4K
  • E.r. Squibb & Sons, L.L.C.$849
  • Lilly USA, LLC$671
  • Sun Pharmaceutical Industries Inc.$246
  • AbbVie$234
  • plus $1K from 19 others
$22,906in research payments, 2019–2025

Across 12 payments — averaging $1908.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$23K

What the payments were for

  • Consulting fees$8,91670%
  • Food & beverage$3,68129%
  • Education$1161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few mohs-micrographic surgery providers in Oregonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$280,892
Medicare patients
423
Services billed
2,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab11$70,818
Fluorouracil86$6,258
Clobetasol Propionate65$6,031
Calcipotriene16$2,053
Metronidazole42$1,824
Imiquimod26$1,265
Doxycycline Monohydrate96$1,221
Tretinoin12$1,006
Ketoconazole56$966
Acitretin12$656
Triamcinolone Acetonide47$299
Doxycycline Hyclate31$253
ValacyclovirValacyclovir Hcl15$246

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →